Hiring in life sciences? Share your open positions with our professional community. Read more Close

Advertisement

High Lipoprotein(a) Is a Predictor of Adverse Events and Heart Failure in Patients With Acute Myocardial Infarction.

Created on 19 Oct 2026

Authors

Yang Wang, Tomoya Ueda, Akihiko Okamura, Saki Nobuta, Atsushi Kyodo, Yasuki Nakada, Yukihiro Hashimoto, Hitoshi Nakagawa, Taku Nishida, Kenji Onoue, Shungo Hikoso

Published in

Circulation journal : official journal of the Japanese Circulation Society. Oct 16, 2026. Epub Oct 16, 2026.

Abstract

Lipoprotein(a) (Lp(a)) is a well-established risk factor for atherosclerotic cardiovascular disease, but its prognostic role after acute myocardial infarction (AMI) remains unclear. This study investigated the association between Lp(a) and major adverse cardiovascular events (MACE), including heart failure (HF) with preserved ejection fraction (HFpEF), in patients with AMI.
We analyzed 1,235 patients with AMI from the NARA-MI registry who underwent emergency percutaneous coronary intervention and had serum Lp(a) measured at admission. Based on receiver operating characteristic curve analysis, patients were categorized into high (≥24 mg/dL) and low (<24 mg/dL) Lp(a) groups. The primary endpoint was MACE, defined as all-cause death, recurrent AMI, HF hospitalization, or unplanned coronary revascularization. During a median follow-up of 3.6 years, 497 MACE events occurred. The incidence of MACE (48.0% vs. 38.3%; P=0.004) and HF hospitalization (9.3% vs. 5.0%; P=0.008) was significantly higher in the high Lp(a) group. In multivariable Cox regression analysis, high-Lp(a) independently predicted MACE (hazard ratio [HR] 1.41; 95% confidence interval [CI] 1.15-1.73; P=0.001) and HF hospitalization (HR 1.87; 95% CI 1.15-3.04; P=0.016). Among patients with HF, 39.7% were classified as HFpEF.
Elevated Lp(a) is independently associated with adverse cardiovascular outcomes after AMI, particularly HF. Measurement of Lp(a) may improve risk stratification after AMI and help identify patients at high risk of developing HF, including HFpEF.

PMID:
42893861
Bibliographic data and abstract were imported from PubMed on 19 Oct 2026.

Read full publication at:
Please sign in to see all details.

Advertisement

Stats

  • Community rating n/a 0 votes
  • Reviewers' rating n/a 0 votes
  • Your rating

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

  • Recommendations n/a n/a positive of 0 vote(s)
  • Views 8
  • Comments 0

Recommended by

  • No recommendations yet.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.

Advertisement